Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study

Autor:	Tony Reiman, John Kuruvilla, Bingshu E. Chen, Ralph M. Meyer, Tanya Skamene, David Good, Stefano Luminari, Nicole B. Laferriere, Michael Crump, Julie Stakiw, David P. LeBrun, Kerry J. Savage, Lois E. Shepherd, Liting Zhu, Laurie H. Sehn, Marina S. Djurfeldt, Denis Soulières, Annette E. Hay
Rok vydání:	2017
Předmět:	Oncology Cancer Research medicine.medical_specialty Phases of clinical research Aggressive lymphoma Deoxycytidine Transplantation Autologous 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine T-cell lymphoma Humans Salvage Therapy business.industry Cytarabine Hematopoietic Stem Cell Transplantation Lymphoma T-Cell Peripheral Hematology medicine.disease Gemcitabine Peripheral T-cell lymphoma Surgery Lymphoma autologous stem cell transplantation randomized phase 3 clinical trial relapse salvage 030220 oncology & carcinogenesis Cisplatin business 030215 immunology medicine.drug
Zdroj:	Leukemialymphoma. 58(10)
ISSN:	1029-2403
Popis:	Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy. At one year, event-free survival (EFS) was 16% and overall survival (OS) was 28%. For PTCL patients, who received autologous stem cell transplant, two-year EFS and OS were 21% and 42%, respectively. Patients with PTCL had inferior OS (HR 0.49, p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46bb5a55a27a996c365540683fa42cb3 https://pubmed.ncbi.nlm.nih.gov/28573916 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.